Advances in Cardiac Tissue Engineering

Tissue engineering has paved the way for the development of artificial human cardiac muscle patches (hCMPs) and cardiac tissue analogs, especially for treating Myocardial infarction (MI), often by increasing its regenerative abilities. Low engraftment rates, insufficient clinical application scalability, and the creation of a functional vascular system remain obstacles to hCMP implementation in clinical settings. This paper will address some of these challenges, present a broad variety of heart cell types and sources that can be applied to hCMP biomanufacturing, and describe some new innovative methods for engineering such treatments. It is also important to note the injection/transplantation of cells in cardiac tissue engineering.

Automated summary

Tissue engineering has opened up new possibilities for treating diseases such as myocardial infarction. However, there are still challenges in clinical applications, such as low engraftment rates and the lack of a functional vascular system. This paper introduces various types and sources of heart cells that can be used in the manufacturing of artificial human cardiac muscle patches, and discusses some new innovative methods.